Multifunctional linker technology containing an N4 group
US-10441607-B1 · Oct 15, 2019 · US
US10201625B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10201625-B2 |
| Application number | US-201214002168-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 1, 2012 |
| Priority date | Mar 1, 2011 |
| Publication date | Feb 12, 2019 |
| Grant date | Feb 12, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Novel radiotracer(s) for Positron Emission Tomography (PET) imaging are described. Novel radiotracer(s) for Positron Emission Tomography (PET) imaging of neuorendocrine tumors are described. Specifically the present invention describes novel [18F]Fluoroethyltriazol-[Tyr3]Octreotate analogs; in particular those that target somatostatin receptors found on the cell surface of gastroenteropancreatic neuorendocrine tumors. The present invention also describes intermediate(s), precursor(s), pharmaceutical composition(s), methods of making, and methods of use of the novel radiotracer(s).
Opening claim text (preview).
What is claimed is: 1. A 2-[ 18 F]fluoroethyl triazole linked [Tyr 3 ]octreotate analogue of formula (5b): wherein: R 2 has the following structure: 2. The 2-[ 18 F]fluoroethyl triazole linked [Tyr 3 ]octreotate analogue according to claim 1 , wherein, R 2 is: 3. A pharmaceutical composition comprising at least one compound of claim 1 and a pharmaceutically acceptable carrier, excipient, or biocompatible carrier. 4. An alkyne linked [Tyr 3 ]octreotate analogue of formula (5a): wherein: R 1 is R 2 has the following structure: 5. The alkyne linked [Tyr 3 ]octreotate analogue according to claim 4 , wherein R 2 is: 6. A method of making the 2-[ 18 F]fluoroethyl triazole linked [Tyr 3 ]octreotate analogue of claim 1 ; the method comprising the step of reacting an alkyne linked [Tyr 3 ]Octreotate analogue having the formula (5a): with 2-[ 18 F]Fluoroethylazide under copper catalyzed click chemistry conditions to form the corresponding 2-[ 18 F]fluoroethyl triazole linked [Tyr 3 ]octreotate analogue having the formula (5b) in claim 1 ; wherein: R 1 in formula (5a) is and R 2 in formula (5a) has the following structure: 7. A method of imaging comprising the steps of administering a compound of claim 1 to a subject and detecting said compound in said subject. 8. The method of detecting neuroendocrine tumor(s) in vivo in a subject comprising the steps of: (i) administering to said subject a compound of claim 1 or a pharmaceutical composition thereof; (ii) allowing said compound or pharmaceutical composition thereof to bind to somatostatin receptor(s) found on the surface of the neuroendocrine tumour(s) in said subject; (iii) detecting signals emitted by the radioisotope in said compound or pharmaceutical composition thereof on said neuroendocrine tumor(s) in said subject; (iv) generating an image representative of the location and/or amount of said signals; and, optionally, (v) determining the distribution and extent of said neuroendocrine tumour(s) in said subject. 9. The method of detecting lung tumor(s) in vivo in a subject comprising the steps of: (i) administering to said subject a compound of claim 1 or a pharmaceutical composition thereof; (ii) allowing said compound or pharmaceutical composition thereof to bind to somatostatin receptor(s) found on the surface of the lung tumour(s) in said subject; (iii) detecting signals emitted by the radioisotope in said compound or pharmaceutical composition thereof on said lung tumor(s) in said subject; (iv) generating an image representative of the location and/or amount of said signals; and, optionally, (v) determining the distribution and extent of said lung tumour(s) in said subject.
Peptides; Proteins · CPC title
the peptide being octreotide or a somatostatin-receptor-binding peptide · CPC title
Heterocyclic compounds · CPC title
conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10) · CPC title
Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins} · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.